Common Contracts
6 similar Common Stock Purchase Warrant contracts by Assembly Biosciences, Inc., Smith Micro Software, Inc.
COMMON STOCK PURCHASE WARRANT SMITH MICRO SOFTWARE, INC.Common Stock Purchase Warrant • November 10th, 2025 • Smith Micro Software, Inc. • Services-prepackaged software
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after Stockholder Approval Date, as such term is defined in Section 4.14 of the PIPE Purchase Agreement (the “Initial Exercise Date”), and on or prior to 5:00 p.m. (New York City time) on the fifth (5th) anniversary of the Stockholder Approval Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Smith Micro Software, Inc., a Delaware corporation (the “Company”), up to _________________ (_______) shares (as subject to adjustment hereunder, the “Warrant Shares”) of common stock of the Company, par value $0.001 per share, (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
COMMON STOCK PURCHASE WARRANT ASSEMBLY BIOSCIENCES, INC.Common Stock Purchase Warrant • November 10th, 2025 • Assembly Biosciences, Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on August 11, 2030 and (ii) the date that is 30 days after the public announcement (whether by press release, document filed or furnished with the Commission (as defined below) or other form of public announcement) that the Company has completed enrollment (of at least 200 patients total) for its Phase 2 clinical study evaluating ABI-5366 vs. valacyclovir, provided that, if such date falls on a day other than a Trading Day, the next day (such earlier date, the “Termination Date”) but not thereafter, to subscribe for and purchase from Assembly Biosciences, Inc., a Delaware corporation (the “Company”), up to [ ] shares (a
COMMON STOCK PURCHASE WARRANT ASSEMBLY BIOSCIENCES, INC.Common Stock Purchase Warrant • November 10th, 2025 • Assembly Biosciences, Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after November 15, 2026 (the “Initial Exercise Date”) and on or prior to December 31, 2026, provided that, if such date falls on a day other than a Trading Day, the next day (the “Termination Date”) but not thereafter, to subscribe for and purchase from Assembly Biosciences, Inc., a Delaware corporation (the “Company”), up to [ ] shares (as subject to adjustment hereunder, the “Warrant Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”). Notwithstanding the foregoing, in the event that, prior to the Initial Exercise Date, the Company publicly announces that it has received at least $75.0 million in the aggregate of non-dilutive capital in connection with a collaboration agreement, then on the date of
COMMON STOCK PURCHASE WARRANT ASSEMBLY BIOSCIENCES, INC.Common Stock Purchase Warrant • November 10th, 2025 • Assembly Biosciences, Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Gilead Sciences, Inc. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on August 11, 2030 and (ii) the date that is 30 days after the public announcement (whether by press release, document filed or furnished with the Commission (as defined below) or other form of public announcement) that the Company has completed enrollment (of at least 200 patients total) for its Phase 2 clinical study evaluating ABI-5366 vs. valacyclovir, provided that, if such date falls on a day other than a Trading Day, the next day (such earlier date, the “Termination Date”) but not thereafter, to subscribe for and purchase from Assembly Biosciences, Inc., a Delaware corporation (the “Company”), u
COMMON STOCK PURCHASE WARRANT SMITH MICRO SOFTWARE, INC.Common Stock Purchase Warrant • November 10th, 2025 • Smith Micro Software, Inc. • Services-prepackaged software
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after May 6, 2026 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on May 6, 2031 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Smith Micro Software, Inc., a Delaware corporation (the “Company”), up to _________________ (_______) shares (as subject to adjustment hereunder, the “Warrant Shares”) of common stock of the Company, par value $0.001 per share, (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
COMMON STOCK PURCHASE WARRANT ASSEMBLY BIOSCIENCES, INC.Common Stock Purchase Warrant • November 10th, 2025 • Assembly Biosciences, Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Gilead Sciences, Inc. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after November 15, 2026 (the “Initial Exercise Date”) and on or prior to December 31, 2026, provided that, if such date falls on a day other than a Trading Day, the next day (the “Termination Date”) but not thereafter, to subscribe for and purchase from Assembly Biosciences, Inc., a Delaware corporation (the “Company”), up to 1,147,960 shares (as subject to adjustment hereunder, the “Warrant Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”). Notwithstanding the foregoing, in the event that, prior to the Initial Exercise Date, the Company publicly announces that it has received at least $75.0 million in the aggregate of non-dilutive capital in connection with a collaboration agreeme